AMAishwarya Mishra

Aishwarya Mishra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aishwarya Mishra has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    One-step flow synthesis and [ 68 Ga]Ga radiolabelling of metal phenolic network nanoparticles for in vivo PET tracking

    by Esmé Shepherd, Amaia Carrascal Miniño, Aishwarya Mishra, Juan Pellico, Jason Sengel, Rafael T. M. de Rosales, Andrew J. Surman

    Metal-phenolic network nanoparticles are growing in popularity as drug delivery vehicles. One-step flow synthesis facilitates the incorporation of short-lived radionuclides, for PET imaging of these nanomaterials.

  • Open Access

    Influences of Ring Sizes and Chiral Substituents on Macrocyclic Chelators for Improving 68 Ga Radiolabeling

    by Yifan Zhu, Zhen Cheng, Junhui Zhang, Liang Feng, Aishwarya Mishra, Rafael T. M. de Rosales, Ryan K. Brown, Nicholas Long, Ga-Lai Law

    68Ga-labeled macrocyclic ligands have been extensively studied and used for positron emission tomography (PET) imaging. Compared with 12-membered DOTA derivatives, NOTA-based chelators with 9-membered macrocyclic rings exhibit more advantageous coordination stability for Ga3+ ions. However, studies of the 10-membered DETA macrocycle are still quite limited. Here, we present the synthesis of four different-sized chiral macrocyclic ligands L1–L4, followed by radiolabeling and stability studies to reveal the influence of ring size and chiral substituents on Ga3+ chelation. In the 68Ga radiolabeling experiments, chiral NOTA L1 exhibits the highest radiochemical yield of 99% at 25 °C. While for the chiral DETA L2/L3 and the chiral DOTA L4, their radiolabeling efficiencies are inferior at room temperature, but remarkable improvements were observed at higher temperatures. L1–L4 all exhibit superior Ga3+ coordination stability than their achiral counterparts, while the chiral DETA L2 with an α-methyl group shows a slightly better performance than its β-analogue L3. Serum stability tests and kinetic studies under acid and alkaline conditions were conducted, highlighting the favorable kinetic inertness of these chiral ligands for potential 68Ga-labeled PET imaging applications.


  • Open Access

    A translatable evaluation tool to study the biodistribution of clinically-available doxorubicin liposomes: PET imaging of [ 89 Zr]Zr-Doxil and [ 89 Zr]Zr-Talidox

    by Amaia Carrascal-Miniño, Aishwarya Mishra, Peter Gawne, Shane Angoh, Juliette Chupin, Jana Kim, Vittorio de Santis, Truc Pham, Fred Bark, Azalea Khan, et al.

    INTRODUCTION: Doxil/Caelyx is a PEGylated liposomal formulation of the chemotherapeutic doxorubicin used in the clinic for Kaposi’s sarcoma, advanced ovarian cancer, progressive multiple myeloma and metastatic breast cancer. Talidox ® , a smaller doxorubicin PEGylated liposome is undergoing clinical trials and has been proposed as an improvement on previous liposomal formulations for the treatment of advanced solid tumors. We aimed to validate an easily translatable radiolabeling method using zirconium-89 ( 89 Zr) that enables quantitative whole-body PET imaging of these formulations to study their biodistribution and pharmacokinetics. METHODS: [ 89 Zr][Zr(oxinate) 4 ] was produced using a kit-based approach followed by use as a direct radiolabeling agent of the liposomal formulations. DFT studies were performed to elucidate the mechanism behind the radiolabeling stability observed within the liposomes. Purified 89 Zr-labelled Doxil/Talidox® liposomes (5 mg/kg doxorubicin dose) were administered in female BALB/c mice bearing 4T1 tumors. PET/CT imaging was acquired at 20 min, 24 h, 48 h, and 72 h, followed by post-mortem biodistribution at 72 h. RESULTS and DISCUSSION: Both formulations were radiolabeled efficiently with high stability in serum in vitro for 72 h. In vivo , both formulations showed high tumor uptake at 72 h (18.5 ± 2.4 % IA/g for Doxil and 20.2 ± 2.3 % IA/g for Talidox). In general, ex vivo biodistribution showed similar uptake values for both formulations with high spleen/liver uptake and low bone uptake, confirming stability. Talidox® showed significantly lower spleen uptake and higher uptake in bone than Doxil. DFT studies confirmed that doxorubicin can form complexes with 89 Zr that are more stable than [ 89 Zr][Zr(oxinate) 4 ], explaining the radiolabeling mechanism and stability results in vitro and in vivo . CONCLUSIONS: Clinically available PEGylated liposomes containing doxorubicin can be efficiently radiolabelled with 89 Zr for PET imaging studies, using a clinically translatable radiolabelling method. Highlights: Doxorubicin-containing liposomes can be labeled with the positron-emitting radionuclide 89 Zr with no impact on their original physicochemical properties. Radiolabeling is stable in vivo and enables imaging and biodistribution studies of the liposomes using positron emission tomography (PET). The radiolabeling method is clinically translatable and would allow early assessment of existing and novel doxorubicin liposome biodistribution in humans or personalized medicine (nanotheranostic) approaches.


  • Open Access

    PET imaging for non-invasive monitoring of 89 Zr-Talidox delivery to the brain following focused ultrasound-mediated blood-brain barrier opening

    by Aishwarya Mishra, Chris Payne, Amaia Carrascal-Miniño, Stefan Halbherr, Antonios N. Pouliopoulos, Rafael T. M. de Rosales

    The blood-brain barrier (BBB) significantly hinders the treatment of central nervous system (CNS) disorders and brain tumors with intact BBB by restricting the entry of most therapeutic agents, including small-molecule drugs and particularly larger macromolecules. Liposomal formulations, such as PEGylated liposomes with long blood half-lives, high drug-carrying capacity, and reduced off-site toxicity, can be useful for brain drug delivery, but their large size often limits BBB penetration. A novel liposomal doxorubicin formulation, Talidox®, with a smaller size (∼36 nm), increased blood circulation half-life, and better stability than previous clinical formulations, can be a suitable choice for brain delivery. This study investigated Talidox® delivery to the brain through focused ultrasound (FUS)-mediated BBB transient opening. Radiolabelling of Talidox® via intraliposomal 89 Zr enabled Positron Emission Tomography (PET) imaging for whole-body non-invasive, real-time monitoring of biodistribution and pharmacokinetics. Following FUS-mediated BBB opening in mice, PET imaging revealed a significant increase in brain uptake compared to non-FUS controls, achieving a 14-fold higher accumulation. Additional validation using passive acoustic detection, microscopy, autoradiography, and cryo-fluorescence tomography demonstrated successful brain distribution that correlated with PET imaging results. These findings underscore the potential of combining Talidox® with FUS for effective, non-invasive drug delivery to the brain and highlight the advantages of PET imaging as a modality for non-invasive, longitudinal quantification of drug delivery to the brain.


  • Open Access

    Exploring In Vivo Metal Chelation as an Approach for Pretargeted PET Imaging

    by Aishwarya Mishra, George Keeling, Jana Kim, Rafael T. M. de Rosales

    Pretargeted PET imaging has emerged as a leading strategy for tracking long-circulating agents such as antibodies and nanoparticle-drug delivery systems with short-lived isotopes. Compared to the conventional direct radiolabeling approach, pretargeting benefits from high sensitivity and spatial resolution of PET while minimizing radiation doses and nonspecific accumulation of radioactivity. In addition, it allows for long-term in vivo tracking possibilities. However, a pretargeting approach that can utilize readily available radionuclides as obtained from the generator/cyclotron without the need of complex radiochemical synthesis is highly desirable. Here, we report a metal chelation pretargeting system based on the 68Ga chelator tris­(hydroxypyridinone) (THP). THP can be radiolabeled at low concentrations with as-obtained generator-produced radionuclide gallium-68 (t1/2 = 68 min) at room temperature and physiological conditions with high efficiency. The bifunctional chelator THP-NCS was conjugated to either PEGylated liposomes or a bone-targeting aminobisphosphonate (pamidronate) to examine the metal chelation pretargeted imaging system in both long-circulating nanomedicines and short-circulating small molecules, respectively. In vivo imaging experiments were performed in healthy BalB/c mice at multiple time points. For liposomal pretargeting, the fraction of liposomes circulating in the blood was efficiently radiolabeled in vivo, but limited in vivo radiolabeling was observed for liposomes that had accumulated in the liver and spleen. The pretargeting of the small-molecule, bone-targeting bisphosphonate THP-Pam showed moderate in vivo radiolabeling in bones. Overall, based on this study, the metal chelation method appears to allow easy pretargeting for agents present in the blood and bones but with limited success in other organs.


  • Open Access

    [68Ga]Ga-THP-tetrazine for bioorthogonal click radiolabelling: pretargeted PET imaging of liposomal nanomedicines

    by Aishwarya Mishra, Amaia Carrascal-Miniño, Jana Kim, Rafael T. M. de Rosales

    A new radiotracer [68Ga]Ga-THP-tetrazine for bioorthogonal click radiochemistry is presented. Its ability for pretargeted imaging of long-circulating liposomal nanomedicines was tested in vitro and in vivo in both healthy and tumour murine models.


  • Open Access

    [68Ga]Ga-THP-Tetrazine for bioorthogonal click radiolabelling: Pretargeted PET imaging of liposomal nanomedicines

    by Aishwarya Mishra, Amaia Carrascal-Miniño, Jana Kim, Rafael T. M. de Rosales

    Pretargeted PET imaging using bioorthogonal chemistry is a leading strategy for the tracking of long-circulating agents such as antibodies and nanoparticle-drug delivery systems with short-lived isotopes. Here, we report the synthesis, characterisation and in vitro/vivo evaluation of a new 68Ga-based radiotracer [68Ga]Ga-THP-Tetrazine ([68Ga]Ga-THP-Tz) for bioorthogonal click radiochemistry and in vivo labelling of agents with slow pharmacokinetics. THP-tetrazine (THP-Tz) can be radiolabelled to give [68/67Ga]Ga-THP-Tz at room temperature in less than 15 minutes with excellent radiochemical stability in vitro and in vivo. [68Ga]Ga-THP-Tz was tested in vitro and in vivo for pretargeted imaging of stealth PEGylated liposomes, chosen as a leading clinically-approved platform of nanoparticle-based drug delivery, and for their known long-circulating properties. To achieve this, PEGylated liposomes were functionalised with a synthesised transcyclooctene (TCO) modified phospholipid. Radiolabelling of TCO-PEG-liposomes with [68/67Ga]Ga-THP-Tz was demonstrated in vitro in human serum, and in vivo using both healthy mice and in a syngeneic cancer murine model (WEHI-164 fibrosarcoma). Interestingly in vivo data revealed that [68Ga]Ga-THP-Tz was able to in vivo radiolabel liposomes present in the liver and spleen, and not those in the blood pool or in the tumour. Overall, these results demonstrate the potential of [68Ga]Ga-THP-Tz for pretargeted imaging/therapy but also some unexpected limitations of this system.

  • Open Access

    Non-invasive radionuclide imaging of trace metal trafficking in health and disease: “PET metallomics”

    by George Firth, Julia E. Blower, Joanna J. Bartnicka, Aishwarya Mishra, Aidan M. Michaels, Alex Rigby, Afnan Darwesh, Fahad Al-Salemee, Philip J. Blower

    Radioactive isotopes of elements from across the periodic table allow for non-invasive imaging of essential metals in health and disease.